SCHEMBL668316

SCHEMBL668316

COc1cccc(CN2CCC(O)(c3ccc(F)c(F)c3)CC2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.62
HTR1D P28221 1/20 0.55
SIGMAR1 Q99720 1/20 0.54
KDM4E B2RXH2 2/20 0.52
CCR3 P51677 1/20 0.49
OPRL1 P41146 2/20 0.48
CCR8 P51685 1/20 0.48
DRD2 P14416 1/20 0.48
DRD3 P35462 1/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
GAA P10253 1/20 0.47
CNR1 P21554 1/20 0.47
CNR2 P34972 1/20 0.47
KCNH2 Q12809 2/20 0.47
MMP1 P03956 1/20 0.47
MMP9 P14780 1/20 0.47
MMP13 P45452 1/20 0.47
ADAM17 P78536 1/20 0.47
LMNA P02545 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL668403 0.90 ALDH1A1 (0.62) ALDH1A1HTR1DSIGMAR1KDM4ECCR3
SCHEMBL666461 0.90 ALDH1A1 (0.62) ALDH1A1HTR1DSIGMAR1KDM4ECCR3
SCHEMBL667793 0.88 ALDH1A1 (0.61) ALDH1A1HTR1DSIGMAR1KDM4ECCR3
SCHEMBL667229 0.86 CCR3 (0.68) ALDH1A1HTR1DSIGMAR1KDM4ECCR3
SCHEMBL666457 0.85 ALDH1A1 (0.70) ALDH1A1HTR1DSIGMAR1KDM4ECCR3
SCHEMBL667773 0.84 ALDH1A1 (0.65) ALDH1A1HTR1DSIGMAR1KDM4ECCR3
SCHEMBL666867 0.83 OPRL1 (0.61) ALDH1A1HTR1DSIGMAR1KDM4ECCR3
SCHEMBL3903967 0.83 CCR3 (0.70) HTR1DKDM4ECCR3OPRL1KMT2A
SCHEMBL4816046 0.82 ALDH1A1 (0.80) ALDH1A1SIGMAR1KDM4ECCR3OPRL1
Hydrochloric Acid SCHEMBL6288091 0.81 ALDH1A1 (0.78) ALDH1A1SIGMAR1KDM4ECCR3OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9045468-B2 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-06-02 US disclosed
EP-2606049-A2 2,5-METHANO-AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN Albany Molecular Research, Inc. (US) 2013-06-26 EP disclosed
US-20120046271-A1 2,5-Methano- and 2,5-Ethano-Tetrahydrobenzazepine Derivatives And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, and Serotonin BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-23 US disclosed
WO-2012024397-A2 2,5-METHANO-AND 2,5-ETHANO-TETRAHYDROBENZAZEPINE DERIVATIVES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2012-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120046271-A1 2,5-Methano- and 2,5-Ethano-Tetrahydrobenzazepine Derivatives And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, and Serotonin HTR2B, HTR1B, HTR5A ALDH1A1 970/4885HTR1D 17/4885SIGMAR1 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.